Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 14.62% is 400% above its 1-year average of 2.92%, near the high end of its 1-year range (0.00%–14.62%).
As of the fiscal period ended Tuesday, June 30, 2026. 400.00% above its 12-month average of 2.92%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 14.62%.
DEBT TO ASSETS RATIO
14.62%
DEBT TO ASSETS RATIO AVG TTM
2.92%
DEBT TO ASSETS RATIO AVG 3Y
0.00%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+400.00%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
+16140.60%
vs the sector median at left
Mineralys Therapeutics, Inc.
Market Cap
$1.99B
Debt to Assets Ratio
14.62%
TTM Avg
2.92%
3Y Avg
0.00%
5Y Avg
N/A
Market Cap
$1.98B
Debt to Assets Ratio
0.03%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.02B
Debt to Assets Ratio
0.08%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.04B
Debt to Assets Ratio
0.41%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.04B
Debt to Assets Ratio
0.73%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.91B
Debt to Assets Ratio
0.75%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.99B | 14.62% | 2.92% | 0.00% | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 0.03% | N/A | N/A | N/A |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 0.08% | N/A | N/A | N/A |
| AxoGen, Inc. (AXGN)vs › | $1.96B | 0.07% | N/A | N/A | N/A |
| Fortrea Holdings Inc. (FTRE)vs › | $2.04B | 0.41% | N/A | N/A | N/A |
| Progyny, Inc. (PGNY)vs › | $2.04B | 0.04% | N/A | N/A | N/A |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | 0.73% | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.06B | 0.91% | N/A | N/A | N/A |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | 0.75% | N/A | N/A | N/A |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | 0.01% | N/A | N/A | N/A |
Debt/Assets
14.6%
Debt/Equity
0.18
Current Ratio
34.46
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 14.62% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2021-12-31 | 0.00% |
